Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
...52-year-old female patient with EGFR-mutated stage IV lung adenocarcinoma...first clinical evidence that the osimertinib and anlotinib-based regimen may be an effective therapy in overcoming resistance mediated by T790M-cis-C797S.
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.